EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy

Thi H O Nguyen, Chhay Lim iD, Masa Lasica, Ashley Whitechurch, Surekha Tennakoon, Natalie R Saunders, Lilith F Allen, Louise C Rowntree, Brendon Y Chua, Lukasz Kedzierski, Hyon-Xhi Tan, Adam K Wheatley und 8 weitere

eJHaem · 2023-02 · 4 (1) · 216-220

DOI: 10.1002/jha2.639 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eJHaem, online erschienen am 20.01.2023. Verfasst von Thi H O Nguyen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BeiGene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 vaccination. Overall, 45 patients (median 72 years old) were recruited; the majority were male (71%), had CLL (76%) and were on zanubrutinib (78%). Seroconversion rates were 65% and 77% following two and three doses, respectively. CD4 + and CD8 + T‐cell response rates increased with third dose. In zanubrutinib‐treated patients, 86% developed either a humoral or cellular response. Patients on zanubrutinib developed substantial immune responses following two COVID‐19 vaccine doses, which further improved following a third dose.

Schlagwörter

Stichwörter der Autor:innen

SARS‐CoV‐2responsevaccinationzanubrutinib

Autor:innen und Institutionen

  • Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia.
  • Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia.
  • Department of Haematology St Vincent's Hospital Fitzroy Victoria Australia.
  • Department of Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia.
  • ARC Centre of Excellence in Convergent Bio-Nano Science and Technology University of Melbourne Melbourne Victoria Australia.
  • Melbourne Sexual Health Centre, Infectious Diseases Department, Alfred Health, Central Clinical School Monash University Melbourne Victoria Australia.

ORCID-Profile: Chhay Lim, Constantine S Tam, Benjamin W Teh

Förderung

  • BeiGene

Zitieren

APA

Nguyen, T. H. O., Lim, C., Lasica, M., Whitechurch, A., Tennakoon, S., Saunders, N. R., Allen, L. F., Rowntree, L. C., Chua, B. Y., Kedzierski, L., Tan, H. X., Wheatley, A. K., Kent, S. J., Karapanagiotidis, T., Nicholson, S., Williamson, D. A., Slavin, M. A., Tam, C. S., Kedzierska, K., & Teh, B. W. (2023). Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy. eJHaem, 4(1), 216-220. https://doi.org/10.1002/jha2.639

Vancouver

Nguyen THO, Lim C, Lasica M, Whitechurch A, Tennakoon S, Saunders NR, et al. Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy. eJHaem. 2023;4(1):216-220. doi:10.1002/jha2.639

BibTeX
@article{Nguyen2023,
  author = {Nguyen, Thi H O and Lim, Chhay and Lasica, Masa and Whitechurch, Ashley and Tennakoon, Surekha and Saunders, Natalie R and Allen, Lilith F and Rowntree, Louise C and Chua, Brendon Y and Kedzierski, Lukasz and Tan, Hyon-Xhi and Wheatley, Adam K and Kent, Stephen J and Karapanagiotidis, Theo and Nicholson, Suellen and Williamson, Deborah A and Slavin, Monica A and Tam, Constantine S and Kedzierska, Katherine and Teh, Benjamin W},
  title = {Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy},
  journal = {eJHaem},
  year = {2023},
  volume = {4},
  number = {1},
  pages = {216--220},
  doi = {10.1002/jha2.639}
}
Kostenlos starten →